Evaluating a tiny biopsy for the presence of cancer is a life-changing event that informs and directs all medical treatment options.
The current diagnostic approach for anatomical pathology is labor intensive, disconnected, and relies on antiquated technologies. LUMEA has developed the first integrated biopsy-to-digital diagnostic platform that improves tissue handling, modernizes the pathology process, and enables the commercialization of diagnostic artificial intelligence (AI).
LUMEA’s technology has been deployed clinically in the urology market and is being used by clinics, laboratories, and pathologists across the country.
LUMEA was founded by Dr. Matthew Leavitt, a Stanford-trained pathologist who has dedicated his career to changing and improving cancer diagnostics. The company has 21 experienced employees all working together to save lives by revolutionizing diagnostic medicine.
John Wirthlin, MBA
Chief Executive Officer
John B. Wirthlin joined LUMEA in 2015 with a passion for dramatically improving diagnostic medicine. Mr. Wirthlin has more than fifteen-years of experience starting and growing innovative life science companies with a proven track record of positioning technologies for investment and commercial development. In 2006 Mr. Wirthlin founded AlloCure Inc. During his tenure at AlloCure he led the company through a successful IND filing and execution of a Phase 1 and Phase 2 clinical trial targeting acute kidney injury. Mr. Wirthlin raised over $45MM from venture capital firms SV Life Sciences, Novo Ventures, Lundbeck Ventures and a corporate partnership with Gambro AB. Prior to AlloCure, Mr. Wirthlin worked for Echelon Biosciences Inc. where he served as Secretary of the Board, Director of Business Development and Director of Operations. Echelon was successfully acquired by Aeterna Zentaris in 2004. Mr. Wirthlin received his MBA from Westminster College with an emphasis on technology commercialization.
Matthew O. Leavitt, MD
Chief Medical Officer
Dr. Matthew O. Leavitt completed his medical training at Dartmouth Medical School and Stanford University Hospitals. After his medical training, he served as department chair at one of Intermountain Healthcare’s regional hospital pathology laboratories. In that role, he became passionate about the acute need to standardize anatomic pathology in order to unleash the full potential of digital imaging and molecular diagnostics in patient’s lives. Motivated by his commitment to improve cancer diagnostics, Dr. Leavitt stepped down from his role at Intermountain Health Care and founded LUMEA in order to established a new technology platform as the standard of excellence in integrated medical diagnostics. Dr. Leavitt actively practices diagnostic medicine in the LUMEA core lab, interpreting clinical biopsy samples, validating LUMEA’s newest technologies, and overseeing LUMEA’s involvement in national multi-institutional clinical trials. He also serves on multiple corporate and strategic advisory boards.
James Thackeray, MBA
Senior Director of Business Development
James Thackeray has over 18 years experience working for some of the top biotechnology and diagnostic organizations in the world. Mr. Thackeray began his career working for Ortho Biotech, a Johnson & Johnson company as a territory manager. He later worked in sales, sales training, sales management and marketing at Genzyme Corporation, Clarient Inc, GE Healthcare and Genomic Health where he helped lead major sales growth each year. Mr. Thackeray is a 2014 SAMY award winner, awarded by Utah Business Magazine to the top sales and marketing individuals in the state of Utah. Mr. Thackeray earned an MBA with honors at The David Eccles School of Business Executive Program at the University of Utah.
Sorin Musat, MD, PhD
Dr. Sorin Musat completed his medical training in 1984 specializing in anatomical pathology. He later received his PhD in Cell Biology and Histology at Carol Davila University of Medicine and Pharmacy in Bucharest, Romania. He completed his postdoctoral studies at the University of Manitoba and the National Research Council Canada / Institute for Biodiagnostics. Early in his career Dr. Musat was a Research Associate at the University of Alberta in Edmonton, and contributed to various projects in experimental cardiology, pulmonary allergy and inflammation, medical microbiology and metabolomics. He also taught medical cell biology and histology and pathophysiology. Dr. Musat’s long time research interests are in the field of experimental pathology and standardizing histology practices. Dr. Musat holds a number of patents in the field of high-throughput pathology and introduced the first tissue microarray in routine clinical diagnostics. Prior to joining LUMEA, Dr. Musat founded HistoBest Inc and Themis where he performed contract research and IVD manufacturing.
Mark Evans, Ph.D.
Vice President of Research and Technology
Dr. Evans has over 30 years of experience leading R&D teams in the areas of automation, measurement systems, product development, and business management. Early in his career Dr. Evans worked for the U.S. Department of Energy where he led the robotics and mechanical systems group at the Pacific Northwest National Lab and later worked at Brigham Young University where he was an Associate Professor of Mechanical Engineering. Dr. Evans left his academic position to start an engineering and automation company called Direct Controls where he served as President and Chief Technology Officer. Dr. Evans joined LUMEA in 2013 as one of its founding members.